Alterity Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Alterity Therapeutics has a total shareholder equity of A$17.6M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$22.2M and A$4.6M respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | n/a |
| Cash | AU$12.32m |
| Equity | AU$17.62m |
| Total liabilities | AU$4.57m |
| Total assets | AU$22.19m |
Recent financial health updates
Recent updates
Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK
Aug 25Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy
Jul 06Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology
Sep 16Alterity Therapeutics names Dr. David Stamler as CEO
Jan 07Alterity and UniQuest partner to reverse bacterial resistance to antibiotics
Dec 21Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders
Nov 16Financial Position Analysis
Short Term Liabilities: ATHE's short term assets (A$22.0M) exceed its short term liabilities (A$4.5M).
Long Term Liabilities: ATHE's short term assets (A$22.0M) exceed its long term liabilities (A$76.5K).
Debt to Equity History and Analysis
Debt Level: ATHE is debt free.
Reducing Debt: ATHE had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATHE has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: ATHE is forecast to have sufficient cash runway for 10 months based on free cash flow estimates, but has since raised additional capital.